AstraZeneca Cash Flow | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | AstraZeneca PLC

AstraZeneca PLC | Cash Flow

Fiscal year is January-December. All values GBP Millions.

2013

2014

2015

2016

2017

2018

Net Income before Extraordinaries

2,090

757

2,009

2,632

1,729

1,495

Depreciation, Depletion & Amortization

1,718

1,919

1,867

1,712

1,905

2,084

Other Funds

991

Funds from Operations

4,701

2,848

2,288

2,489

2,945

2,587

Changes in Working Capital

106

1,523

686

479

Net Operating Cash Flow

4,807

4,372

2,256

3,176

2,906

2,108

Capital Expenditures

1,317

1,671

1,825

1,715

1,258

Sale of Fixed Assets & Businesses

Purchase/Sale of Investments

179

322

347

Net Investing Cash Flow

1,921

4,356

2,855

3,045

1,935

Cash Dividends Paid - Total

2,214

2,138

2,282

2,639

2,733

Issuance/Reduction of Debt, Net

397

2,862

1,610

435

Net Financing Cash Flow

1,949

1,643

575

981

2,280

Net Change in Cash

895

1,719

835

1,360

Free Cash Flow

4,332

3,757

1,387

2,104

1,876

Net Assets from Acquisitions

747

2,715

1,980

2,127

1,463

Other Sources

740

1,058

1,068

Change in Capital Stock

308

169

Exchange Rate Effect

About AstraZeneca

View Profile

Address	Cambridge Biomedical Campus Cambridge Cambridgeshire CB2 0AA United Kingdom
Employees	-
Website	http://astrazeneca.com
Updated	07/08/2019
AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta.